Evidation Insights from 165,000 People Show Continued Growth Potential Amid Uneven Adoption in the GLP-1 Market
Among 119,000 surveyed individuals actively trying to lose weight, 24% had ever used prescription medication for weight management and 15% had ever used a GLP-1, suggesting significant room for continued market growth as adoption varies by age, gender, and income.
Evidation, the leader in direct-from-participant real-world data and health research, today announced new insights from multiple, longitudinal surveys showing that the market for GLP-1s and prescription weight management is growing rapidly, but unevenly, across demographic subpopulations including age, gender, and income. The insights point to a highly segmented market, where access, affordability, awareness, and treatment pathways may shape who starts treatment and who stays on it over time.
Among 119,000 people who report that they are actively trying to lose weight, only 15% reported ever trying a GLP-1, underscoring the scale of the population still outside of prescription treatment pathways. These insights also show higher levels of GLP-1 experience, defined as current or prior use, among adults ages 40-59, women, and higher-income respondents, reinforcing that the market is segmented and that treatment pathways may differ by population.
